DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— CNBC's Michael Bloom - 2 Morgan Stanley - 1 Needham - 1 Joseph Stringer - 1 dealmaking - 1 Stringer - 1 erosive - 1 it's - 1
Top related locs:
New Jersey U.S
Top related orgs:
Rocket Pharmaceuticals - 4 Federal Reserve - 2 CNBC Pro - 2 Nasdaq - 1 Oncology - 1 Immunology - 1 Phathom Pharmaceutical - 1 Pharmaceuticals - 1

Search resuls for: "Rocket Pharmaceuticals"


7 mentions found


☆ Biotech stocks are ready to break out. They just need one more thing
  + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +5 min
While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.
Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey
☆ Analysts love these biotech stocks, giving 4 more than 100% upside
  + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.
Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals
☆ This biotech stock is set to nearly quadruple on the back of its advanced gene therapy products, says Cantor Fitzgerald
  + stars: | 2023-10-24 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +1 min
Rocket Pharmaceuticals shares are poised to nearly quadruple as it rolls out its lineup of late-stage targeted gene therapies, according to Cantor Fitzgerald. RCKT YTD mountain RCKT YTD chart Analyst Josh Schimmer called the stock one of his "top picks" as its products address unmet medical needs. It also benefits from a "thoughtful management team with a knack for identifying compelling gene therapy programs," he said. Schimmer is extremely bullish on Rocket's portfolio of advanced gene therapy products. "RCKT should be stacking larger and larger gene therapy programs," the analyst wrote.
Persons: Cantor Fitzgerald, Josh Schimmer, Schimmer, — CNBC's Michael Bloom Organizations: Rocket Pharmaceuticals
☆ Small caps are finally starting to join the rally in June. Here's how to play their comeback
  + stars: | 2023-06-08 | by ( Fred Imbert | ) www.cnbc.com   time to read: +3 min
Small stocks are making big moves this month, which could signal good news is ahead for Wall Street. The Russell 2000 , which is made up of small-cap names, is higher by 7% in June. .RUT 1M mountain Russell 2000 in past month "Moreover, small-caps have traditionally served as a bellwether in terms of the broader economic landscape," Krosby added. On top of that, Wolfe Research strategist Rob Ginsberg warned that the Russell 2000 could run into some technical resistance after the recent rally. That said, there are ways investors can try to capitalize on the small-cap rally.
Persons: Russell, Quincy Krosby, Krosby, Wolfe, Rob Ginsberg, Ginsberg Organizations: Financial, of Labor Statistics, Wolfe Research, CNBC Pro, Energy, NOVA, Beam Therapeutics, Rocket Pharmaceuticals, Arrowhead Pharmaceuticals Locations: U.S
☆ Morgan Stanley sees this gene therapy stock doubling from here
  + stars: | 2023-02-01 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Rocket Pharmaceuticals could soar as a trial with blockbuster sales potential enters a pivotal phase, according to Morgan Stanley. Analyst Michael Ulz initiated the stock at overweight with a $45 price target. That target share price implies the stock will rally 107.1% from Tuesday's close. Ulz called Rocket a "leading gene therapy company" that can find the best treatments for a given disease. RP-A501, a one-time gene therapy treatment, has shown "promising" phase one results among adults and children, Ulz said.
☆ Here are Wednesday's biggest analyst calls: Apple, Amazon, Target, AMD, Exxon, Snap, Nike & more
  + stars: | 2023-02-01 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Morgan Stanley reiterates PayPal as overweight Morgan Stanley said it's standing by shares of PayPal but that Apple Pay is a formidable competitor for the company. Morgan Stanley initiates Rocket Pharmaceuticals as overweight Morgan Stanley said in its initiation of Rocket Pharmaceuticals that it likes the company's pipeline. Morgan Stanley reiterates Amazon as overweight Morgan Stanley said it's bullish on Amazon's Buy with Prime service for merchants. Morgan Stanley reiterates Walmart as overweight Morgan Stanley said growth remains strong for the Walmart's subscription service, Walmart+. " Morgan Stanley reiterates McDonald's as overweight Morgan Stanley said the fast food giant is well positioned for 2023 after it reported strong earnings on Tuesday.
☆ Cramer's lightning round: Plug Power must get expenses under control
  + stars: | 2022-11-14 | by ( Krystal Hur | ) www.cnbc.com   time to read: +1 min
Rocket Pharmaceuticals Inc : "This is a very early stage company that has a lot in the pipe. If you get a bunch of them, I think you're going to be fine." Loading chart...Anavex Life Sciences Corp : "This is another one that I kind of like, I've got to tell you. Loading chart...Ryan Specialty Holdings Inc : "I've got to find out what the hell went wrong with that one last week. Loading chart...Shockwave Medical Inc : "Shockwave's a good company.
0 next >>
Total: 7